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individual born in 2005 returns a lifetime positive NPV to the
government of £160,069 with a break-even point (ie. where the
NPV becomes positive) at age 31. A child with similar charac-
teristics, but conceived using IVF, has a lifetime NPV of
£144,000 with a break-even point at age 33. Sensitivity analysis
indicated that these results are sensitive to assumptions about the
working age interval, inﬂation rate, discount rate, and increasing
age related health costs. CONCLUSION: Despite modelling limi-
tations, we conclude that under reasonable assumptions IVF
costs are relatively insigniﬁcant vis-à-vis other costs and beneﬁts
to government. While the model does not forecast the full eco-
nomic beneﬁts associated with investment in IVF, it does dem-
onstrate the potential long-term ﬁnancial returns of improved
access to IVF services.
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OBJECTIVES: To determine whether the protease inhibitor (PI)
darunavir boosted with low dose ritonavir (DRV/r) is cost-
effective, compared to currently available PIs, as part of highly
active anti-retroviral therapies (HAART), in highly pre-treated
HIV-1-infected adults who failed >1 PI-containing regimen in
European healthcare settings. This analysis included Belgium,
Italy and Sweden and focused on the payer perspective.
METHODS: A Markov model was adapted which contains 6
health states deﬁned by CD4+ T-cell-count range (<50, 51–100,
101–200, 201–350, 351–500 and >500 cells/mm3) and a state
“death” (Mauskopf et al, 2006). Clinical trial (POWER1&2)
data were used to model the composition of HAART regimens,
patient characteristics and transition probabilities during DRV/r
or comparator PI(/r) treatment, both combined with optimised
background regimen (OBR). After treatment failure, patients
were assumed to switch to tipranavir/r-containing regimens
((TPV/r)+OBR). Transition probabilities during TPV/r treatment
were obtained from published clinical trials. Utility values and
HIV-related mortality were obtained from published literature.
Published relative risks of non-HIV mortality in HIV patients
were applied to country-speciﬁc all-cause mortality statistics.
Non-HAART-related costs in each model state were derived from
observational studies in each country. Costs and effects were
discounted according to local guidelines. The quality-adjusted
lifetime incremental cost-effectiveness ratio (ICER) was calcu-
lated for the base-case. Univariate and probabilistic sensitivity
analyses were applied. RESULTS: For Sweden, Italy and Belgium
respectively, quality-adjusted life year (QALY) gains of 1.142,
1.171 and 1.397 were predicted for patients treated with DRV/r
in the base-case analysis. The base-case ICER for DRV/r was
12,211€/QALY, 16,668€/QALY and 12,584€/QALY respectively.
The DRV/r ICER remained consistently below the often quoted
threshold of 30,000€/QALY throughout extensive sensitivity
analyses. The probability of an ICER below 30,000€/QALY was
above 92% in all countries. CONCLUSION: DRV/r is predicted
to be cost-effective versus currently available PIs in highly pre-
treated HIV-1-infected adults in different European health care
settings.
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OBJECTIVES: To assess the cost-effectiveness of Intrathecal
Baclofen Therapy (ITB) versus current therapies in low level
disabled spasticity. METHODS: Two simulation models have
been constructed to assess the effectiveness, cost and cost-
effectiveness of various treatment sequences based on current
medical practices established by an international expert panel.
The ﬁrst model simulates current therapies using various
sequences of physical treatment only, oral treatments, focal spas-
ticity treatments, neuro-surgery and nursing. The second model
simulates strategies starting with ITB as the ﬁrst line treatment,
then various sequences of 2d, 3rd or 4th lines treatments includ-
ing ITB dose adjustment, explantation, oral treatments, focal
spasticity treatments, neurosurgery or nursing. The model used a
simulation decision framework and a 2-year time horizon over
four 6 months intervals. A successful treatment has been deﬁned
as a patient or caregiver satisfaction + change of 1 point in the
Ashworth score. Direct medical costs have been collected in the
frame of the French health care system. Effectiveness and cost
parameters have been included in the model according to speciﬁc
distribution shapes in order to take into account medical prac-
tices variability. Probabilistic sensitivity analyses were conducted
using 5000 Monte-Carlo simulations taking into account speciﬁc
distribution shapes for each cost and effectiveness parameters.
RESULTS: ITB as ﬁrst line strategy is the dominant strategy over
2 years, providing greater treatment success rate (78.7% versus
59.3%, p < 0.001), lower costs (59,391 Euros versus 88,272
Euros, p < 0.001) and lower cost-effectiveness (75,204 Euros/
success versus 148,822 Euros/success, p < 0.001) than current
strategies. CONCLUSION: This robust cost-effectiveness mod-
eling is the ﬁrst study assessing the cost-effectiveness of various
treatment sequences in disabled spasticity according to current
medical practices. This study establishes that introducing ITB as
the ﬁrst line therapy is a dominant strategy (more effective and
less costly) over a time period of 2 years.
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OBJECTIVES: To estimate the cost-effectiveness of a new treat-
ment (natalizumab) for multiple sclerosis (MS) compared to
current standard therapy with disease-modifying drugs (DMDs)
in Sweden. METHODS: A Markov model was constructed to
illustrate disease progression based on functional disability
(EDSS). Disease progression while on treatment with natali-
zumab was based on a two-year placebo-controlled clinical trial
in 942 patients (AFFIRM). Progression while on treatment with
current DMDs was estimated from a matched sample of 512
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